$MMED

MiniMed Group, Inc.

MiniMed develops, manufactures and markets diabetes management technologies for people with diabetes who require intensive insulin therapy, including people with type 1 diabetes and some with type 2 diabetes. Its offerings include automated insulin delivery systems, smart multiple daily injection systems, insulin pumps and pens, continuous glucose monitoring sensors, consumables, supplies, software and services. The MiniMed 780G system combines an insulin pump, glucose sensor and dosing algorithm; the MiniMed Go system pairs the InPen smart insulin pen with a CGM sensor and related apps and services. MiniMed earns money primarily by selling these devices and related consumables, software and services. It distributes most of its U.S. products through the durable medical equipment channel and a smaller percentage through pharmacies. The company is headquartered in Northridge, California, and operates manufacturing facilities in California and Puerto Rico.

AlphAI earnings readQ1 FY27 · SEP 1 · NEXT NOV 24MiniMed Delivers Strong Start to Fiscal Year 2027 with U.S. Growth AccelerationVerdict: strong

Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.

4
0
2

No SEC Form 4 filings for $MMED in the last 30 days.

See all $MMED insider activity →
High

Mizuho reiterates Outperform on MiniMed stock, cites product momentum

Mizuho reiterated an Outperform rating and $28.00 price target for MiniMed Group (MMED), citing strong product launches and regulatory approvals. The stock has gained nearly 40% over six months despite a recent 9.6% decline. MiniMed secured FDA clearance for its MiniMed Fit patch pump ahead of schedule and plans a U.S. launch in Spring 2027. Analysts predict profitability this year after a prior loss of $1.19 per share.

MiniMed Group, Inc. announced that the U.S. Food and Drug Administration has cleared the MiniMed Fit™ patch pump, MiniMed’s first tubeless insulin pump…

MiniMed Group, Inc. (MMED) filed an SEC Form 8-K — Regulation FD Disclosure. Item 7.01 Regulation FD Disclosure. On November 16, 2026, MiniMed Group, Inc. (“MiniMed”) announced that the U.S. Food and Drug Administration (the “FDA”) has cleared the MiniMed Fit™ patch pump, MiniMed’s first tubeless insulin pump, offering people with diabetes a new different

MMED sentiment & insider activity

Over the past 7 days, AlphAI's AI scored 6 news stories mentioning MMED (MiniMed Group, Inc.). Coverage has skewed bullish: 4 bullish, 0 neutral, and 2 bearish.

Recent MMED coverage spans financial news, corporate actions and regulation.

What's driving MMED

AlphAI scores every news story that mentions MMED with an AI model for sentiment and relevance, and aggregates insider trades from MiniMed Group, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.

News on $MMED

Score

Mizuho reiterates Outperform on MiniMed stock, cites product momentum

Mizuho reiterated an Outperform rating and $28.00 price target for MiniMed Group (MMED), citing strong product launches and regulatory approvals. The stock has gained nearly 40% over six months despite a recent 9.6% decline. MiniMed secured FDA clearance for its MiniMed Fit patch pump ahead of schedule and plans a U.S. launch in Spring 2027. Analysts predict profitability this year after a prior loss of $1.19 per share.

$MMEDMedAI 8/10Clinical / regulatory· FDA approval

MiniMed Group, Inc. announced that the U.S. Food and Drug Administration has cleared the MiniMed Fit™ patch pump, MiniMed’s first tubeless insulin pump…

MiniMed Group, Inc. (MMED) filed an SEC Form 8-K — Regulation FD Disclosure. Item 7.01 Regulation FD Disclosure. On November 16, 2026, MiniMed Group, Inc. (“MiniMed”) announced that the U.S. Food and Drug Administration (the “FDA”) has cleared the MiniMed Fit™ patch pump, MiniMed’s first tubeless insulin pump, offering people with diabetes a new different

$MMEDLowExec change· appointed

MiniMed Appoints Dr. David Segal as Chief Medical Officer

MiniMed (MMED) appointed Dr. David Segal as Chief Medical Officer, succeeding Dr. Robert Vigersky. Segal has 20 years of diabetes care experience and previously led innovation at Parkview Health. CEO Que Dallara highlighted Segal's expertise in technology-driven diabetes care. Vigersky will transition to an emeritus role by 2027.

$MDTHighM&A· completed

Medtronic plc (MDT): Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Medtronic plc (MDT) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Exhibit 99.1 Medtronic Completes Separation of MiniMed Group, Inc. GALWAY, Ireland, October 15, 2026 – Medtronic plc (Medtronic; NYSE: MDT) today announced the completion of its separation of MiniMed Group, Inc. (MiniMed; Nasdaq: MMED). “I’m incredibly proud of what MiniMed and M

$MMEDMedM&A· target · completed

MiniMed Group, Inc. (MMED): Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

MiniMed Group, Inc. (MMED) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Exhibit 99.1 MiniMed Completes Separation from Medtronic NORTHRIDGE, Calif., October 15, 2026 – MiniMed (Nasdaq: MMED) today announced the completion of its separation from Medtronic plc (“Medtronic”; NYSE: MDT), marking its first day as a fully independent company. “Today marks

$MMEDLowShareholder vote

MiniMed Group, Inc. (MMED): Submission of Matters to a Vote of Security Holders

MiniMed Group, Inc. (MMED) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. Item 5.07 Submission of Matters to a Vote of Security Holders. MiniMed Group, Inc. (the “Company”) held its 2026 Annual Meeting of Stockholders on October 9, 2026 (the “Annual Meeting”), at which stockholders voted on the following four proposals. All matters voted on at the Annu

Related tickers